Biotechnology company Kyverna Therapeutics Inc (KYTX) recently announced that its chimeric antigen receptor T cell therapy Miv-Cel (KYV-101) for stiff person syndrome (SPS) has completed the primary analysis in the clinical trial named KYSA-8.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Trump promotes the "manufacturing card" again for midterm elections: Audi to invest $4 billion in a U.S. plant, plans annual production of 200,000 SUVs
Audi plans to invest 4 billion dollars to build a factory in the United States, with an annual production capacity of 200,000 SUVs, creating 4,500 jobs. The German labor union criticized the CEO's supportive attitude as "puzzling," and the final decision will be made by the Volkswagen supervisory board.
Price increases haven't suppressed demand! JPMorgan weekly tracker: Apple (AAPL.US) iPhone 18 Pro delivery cycle matches last year; Duo still out of stock for three months
A tracking report by JPMorgan shows that the delivery period for the iPhone Duo continues to be around three months, and it is unavailable for in-store pickup in all monitored regions. Meanwhile, the delivery periods for the iPhone 18 Pro and Pro Max are steadily returning to normal, with the global average delivery period having reverted to the same level as the same period last year.
Crypto prices
More
